177Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer
Details
Publication Year 2023-02,Volume 306,Issue #2,Page e220859
Journal Title
Radiology
Publication Type
Review
Abstract
A 76-year-old man with metastatic castration-resistant prostate carcinoma progressing with antiandrogen and taxane therapy was treated with lutetium 177 prostate-specific membrane antigen (PSMA)-617 and showed marked biochemical and imaging response, with improvement in clinical status and osseous pain. A summary of nuclear medicine theranostics with emphasis on PSMA targeting agents is presented.
Publisher
Radiological Society of North America
Keywords
Aged; Humans; Male; Prostate/pathology; Prostate-Specific Antigen; *Prostatic Neoplasms, Castration-Resistant/chemically induced/drug; therapy/pathology; Treatment Outcome
Department(s)
Cancer Imaging
PubMed ID
36125377
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-13 07:55:10
Last Modified: 2023-06-13 07:56:08

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙